Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis
Abstract Background This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). Methods We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Librar...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | Journal of Orthopaedic Surgery and Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13018-018-0794-1 |
| _version_ | 1818037053987749888 |
|---|---|
| author | Qifeng Li Baoshan Xu |
| author_facet | Qifeng Li Baoshan Xu |
| author_sort | Qifeng Li |
| collection | DOAJ |
| description | Abstract Background This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). Methods We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and Chinese Wanfang database from inception up to October 2017. Included patients were prepared for THA and were separated into two groups: intervention group (risedronate treatment) and control group (placebo treatment). BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. Results Five randomized controlled trials (RCTs) involving 259 patients (risedronate group = 127, control group = 132) were finally included in this meta-analysis. Meta-analysis indicated that oral risedronate significantly increased the BMD change in Gruen zone 1. However, there was little clinical significance between the risedronate and control group in terms of the Gruen zones 2, 3, and 7. Oral risedronate significantly increased the Harris hip scores compared with the control group (P < 0.05). Conclusion Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. Due to the limited included studies, more high-quality randomized controlled trials (RCTs) were still needed to identify the efficacy of risedronate for bone loss in THA. |
| first_indexed | 2024-12-10T07:20:44Z |
| format | Article |
| id | doaj.art-bd93b5e85f51485a80b938d6cd3a2a00 |
| institution | Directory Open Access Journal |
| issn | 1749-799X |
| language | English |
| last_indexed | 2024-12-10T07:20:44Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Orthopaedic Surgery and Research |
| spelling | doaj.art-bd93b5e85f51485a80b938d6cd3a2a002022-12-22T01:57:50ZengBMCJournal of Orthopaedic Surgery and Research1749-799X2018-06-011311910.1186/s13018-018-0794-1Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysisQifeng Li0Baoshan Xu1Graduate school, Tianjin Medical UniversityDepartment of orthopaedics, Tianjin HospitalAbstract Background This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). Methods We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and Chinese Wanfang database from inception up to October 2017. Included patients were prepared for THA and were separated into two groups: intervention group (risedronate treatment) and control group (placebo treatment). BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. Results Five randomized controlled trials (RCTs) involving 259 patients (risedronate group = 127, control group = 132) were finally included in this meta-analysis. Meta-analysis indicated that oral risedronate significantly increased the BMD change in Gruen zone 1. However, there was little clinical significance between the risedronate and control group in terms of the Gruen zones 2, 3, and 7. Oral risedronate significantly increased the Harris hip scores compared with the control group (P < 0.05). Conclusion Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. Due to the limited included studies, more high-quality randomized controlled trials (RCTs) were still needed to identify the efficacy of risedronate for bone loss in THA.http://link.springer.com/article/10.1186/s13018-018-0794-1RisedronateTotal hip arthroplastyMeta-analysis |
| spellingShingle | Qifeng Li Baoshan Xu Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis Journal of Orthopaedic Surgery and Research Risedronate Total hip arthroplasty Meta-analysis |
| title | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
| title_full | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
| title_fullStr | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
| title_full_unstemmed | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
| title_short | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
| title_sort | oral risedronate increases gruen zone bone mineral density after primary total hip arthroplasty a meta analysis |
| topic | Risedronate Total hip arthroplasty Meta-analysis |
| url | http://link.springer.com/article/10.1186/s13018-018-0794-1 |
| work_keys_str_mv | AT qifengli oralrisedronateincreasesgruenzonebonemineraldensityafterprimarytotalhiparthroplastyametaanalysis AT baoshanxu oralrisedronateincreasesgruenzonebonemineraldensityafterprimarytotalhiparthroplastyametaanalysis |